Emory University

Clinical trials, superficially speaking, might seem custom-made for low-income patients with cancer.

Findings published in the Journal of the Pediatric Infectious Diseases Society showed that nearly 2% of children admitted to 32 children’s hospitals in the United States received at least one antimicrobial agent for conditions that were not infection-related.

CHICAGO — The Conquer Cancer Foundation of ASCO presented ASCO Annual Meeting Merit Awards to more than 100 oncology professionals.

CHICAGO — The use of expanded eligibility criteria would allow nearly twice as many people with non-small cell lung cancer to participate in clinical trials, according to data presented at ASCO Annual Meeting.

Drinking 100% fruit juices and other sugar-sweetened beverages such as soft drinks, sodas and fruit-flavored drinks was associated with increased all-cause mortality, according to findings recently published in JAMA Network Open.

The American College of Cardiology Scientific Session produced some groundbreaking findings with major implications for the practice of interventional cardiology. Most stunning was two trials that showed transcatheter aortic valve replacement bested surgery in low-risk patients with severe aortic stenosis; reaction to those data appears in the Cover Story.

Early treatment with lenalidomide significantly reduced the risk for progression of high-risk smoldering multiple myeloma to symptomatic multiple myeloma, according to results of a randomized trial scheduled for presentation at ASCO Annual Meeting.

Recent policy changes enacted between 1998 and 2015 to expand insurance coverage for mental health services was associated with increased prevalence of depression treatment without increasing prices or total spending, according to a study published in JAMA Psychiatry.

NEW YORK — Nabil F. Saba, MD, FACP, professor of hematology/medical oncology and otolaryngology and director of the head and neck oncology program at Winship Cancer Institute at Emory University, spoke at HemOnc Today New York about combination approaches for head and neck squamous cell carcinoma in the immunotherapy era.

Maintenance treatment with combination nivolumab/ipilimumab or nivolumab alone did not improve OS compared with placebo in patients with extensive-stage small cell lung cancer, according to results from the phase 3 CheckMate 451 study presented at European Lung Cancer Congress.